CND Life Sciences recently opened a new Innovation Laboratory in Scottsdale aimed at advancing neurodiagnostics, featuring research and product development.

CND Life Sciences announced significant financing to enhance its Syn-One Test® platform and drive advancements in precision neurology diagnostics.

CND Life Sciences' Syn-One® services measure alpha-synuclein in Parkinson’s research, showcasing potential for drug development in clinical trials.

CND Life Sciences celebrates the completion of its 50,000th Syn-One Test, a breakthrough in diagnosing synucleinopathies, enhancing patient care nationwide.

CND Life Sciences has been awarded a $3 million NIH grant to explore the link between essential tremor and the risk of Parkinson's disease. Their groundbreaking study examines biomarkers in patients to enhance early intervention approaches.

CND Life Sciences has received the FDA's Breakthrough Device Designation for its Syn-One Test, aiding in the diagnosis of synucleinopathies in patients.

CND Life Sciences unveiled promising results from their Syn-One Test, detecting alpha-synuclein in skin biopsies of patients with REM sleep behavior disorder, highlighting its potential as a diagnostic tool.

CND Life Sciences announces successful $13.5 million Series A equity round, aiming to enhance neurodiagnostics and patient care.

CND Life Sciences will present three pivotal clinical trial updates on their skin biopsy tool for dementia diagnostics at the upcoming AAN 2025.

CND Life Sciences published a study demonstrating the Syn-One Test's effectiveness in diagnosing neurodegenerative diseases accurately.